SCHEMBL14612436

SCHEMBL14612436

FNCc1cccc(F)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.54
IDO1 P14902 2/20 0.52
AGXT P21549 2/20 0.52
KDM1A O60341 2/20 0.49
MPO P05164 2/20 0.49
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
SLC6A2 P23975 1/20 0.47
HRH2 P25021 1/20 0.47
DRD3 P35462 1/20 0.47
SLC6A3 Q01959 1/20 0.47
MIF P14174 1/20 0.47
FFAR1 O14842 1/20 0.46
SCN8A Q9UQD0 1/20 0.46
SRC P12931 1/20 0.46
ALDH1A1 P00352 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
APP P05067 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25588040 0.84 TAAR1 (0.52) TAAR1IDO1AGXTKDM1AMPO
SCHEMBL6896418 0.82 TAAR1 (0.50) TAAR1IDO1AGXTKDM1AMPO
SCHEMBL159689 0.82 TAAR1 (0.66) TAAR1IDO1AGXTMPOSCN8A
SCHEMBL8221821 0.82 CYP3A4 (0.59) TAAR1IDO1AGXTKDM1AMPO
SCHEMBL4573287 0.82 TAAR1 (0.50) TAAR1IDO1AGXTKDM1AMPO
SCHEMBL24870836 0.82 TAAR1 (0.50) TAAR1IDO1AGXTKDM1AMPO
SCHEMBL4975466 0.82 TAAR1 (0.50) TAAR1IDO1AGXTKDM1AMPO
SCHEMBL30009921 0.82 TAAR1 (0.66) TAAR1IDO1AGXTMPOSCN8A
SCHEMBL20804366 0.82 MPO (0.54) TAAR1IDO1AGXTKDM1AMPO
SCHEMBL31612206 0.82 CYP3A4 (0.59) TAAR1IDO1AGXTKDM1AMPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043095-A1 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use IPSEN PHARMA S.A.S. (FR) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043095-A1 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use SSTR2, SSTR5, SSTR3 TAAR1 112/4885IDO1 598/4885AGXT 3945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.